- Home
- SLVM vs NVCR Comparison
SLVM vs NVCR Comparison
Compare SLVM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLVM
- NVCR
- Stock Information
- Founded
- SLVM 1898
- NVCR 2000
- Country
- SLVM United States
- NVCR Jersey
- Employees
- SLVM N/A
- NVCR N/A
- Industry
- SLVM Paper
- NVCR Medical/Dental Instruments
- Sector
- SLVM Basic Materials
- NVCR Health Care
- Exchange
- SLVM Nasdaq
- NVCR Nasdaq
- Market Cap
- SLVM 3.5B
- NVCR 3.0B
- IPO Year
- SLVM N/A
- NVCR 2015
- Fundamental
- Price
- SLVM $85.39
- NVCR $33.00
- Analyst Decision
- SLVM Hold
- NVCR Buy
- Analyst Count
- SLVM 3
- NVCR 5
- Target Price
- SLVM $89.00
- NVCR $33.40
- AVG Volume (30 Days)
- SLVM 227.9K
- NVCR 1.8M
- Earning Date
- SLVM 11-12-2024
- NVCR 10-30-2024
- Dividend Yield
- SLVM 2.06%
- NVCR N/A
- EPS Growth
- SLVM N/A
- NVCR N/A
- EPS
- SLVM 6.41
- NVCR N/A
- Revenue
- SLVM $3,767,000,000.00
- NVCR $577,738,000.00
- Revenue This Year
- SLVM $3.41
- NVCR $19.13
- Revenue Next Year
- SLVM N/A
- NVCR $5.33
- P/E Ratio
- SLVM $13.45
- NVCR N/A
- Revenue Growth
- SLVM 2.25
- NVCR 14.63
- 52 Week Low
- SLVM $44.94
- NVCR $11.70
- 52 Week High
- SLVM $98.02
- NVCR $34.00
- Technical
- Relative Strength Index (RSI)
- SLVM 42.78
- NVCR 71.04
- Support Level
- SLVM $85.55
- NVCR $31.45
- Resistance Level
- SLVM $88.86
- NVCR $34.00
- Average True Range (ATR)
- SLVM 2.26
- NVCR 2.49
- MACD
- SLVM -0.72
- NVCR 0.45
- Stochastic Oscillator
- SLVM 8.71
- NVCR 92.37
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.